Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#91 / 200 Total
PHVS - Pharvaris NV - Stock Price Chart
TickerPHVS [NASD]
CompanyPharvaris NV
CountryNetherlands
IndustryBiotechnology
Market Cap852.75MEPS (ttm)-2.71
P/E-EPS this Y15.57%
Forward P/E-EPS next Y-6.02%
PEG-EPS past 5Y-28.27%
P/S-EPS next 5Y20.59%
P/B2.57EPS Q/Q43.03%
Dividend-Sales Q/Q-
Insider Own75.13%Inst Own36.80%
Insider Trans0.00%Inst Trans-0.09%
Short Float0.10%EarningsApr 10/a
Analyst Recom1.43Target Price33.33
Avg Volume113.72K52W Range7.93 - 33.00
Apr-10-24 09:52PM PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 (InvestorPlace)
04:10PM Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
04:08PM Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer (GlobeNewswire)
Apr-04-24 06:50AM Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference (GlobeNewswire)
Mar-18-24 06:50AM Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses (GlobeNewswire) +6.34%
Mar-06-24 06:50AM Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses (GlobeNewswire) +5.86%
Mar-05-24 06:50AM Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 (GlobeNewswire)
Feb-22-24 06:50AM Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting (GlobeNewswire)
Feb-16-24 06:50AM Pharvaris Announces Extraordinary Meeting of Shareholders (GlobeNewswire)
Jan-26-24 06:50AM Pharvaris to Present at the WSAAI Annual Meeting 2024 (GlobeNewswire)
ELTX - Elicio Therapeutics Inc. - Stock Price Chart
TickerELTX [NASD]
CompanyElicio Therapeutics Inc.
CountryUSA
IndustryBiotechnology
Market Cap99.74MEPS (ttm)-6.15
P/E-EPS this Y45.69%
Forward P/E-EPS next Y-10.85%
PEG-EPS past 5Y3.87%
P/S-EPS next 5Y-
P/B8.22EPS Q/Q56.43%
Dividend-Sales Q/Q-
Insider Own28.52%Inst Own3.46%
Insider Trans71.04%Inst Trans-2.78%
Short Float0.54%EarningsMar 29/b
Analyst Recom2.00Target Price11.00
Avg Volume64.25K52W Range2.96 - 24.39
Apr-05-24 04:30PM Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting (GlobeNewswire) +17.69%
Apr-02-24 07:53AM ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Mar-29-24 08:30AM Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-18-24 08:00AM Elicio Therapeutics Announces $6.0 Million Private Placement Financing (GlobeNewswire) +28.00%
Mar-06-24 08:30AM Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-05-24 08:30AM Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-25-24 09:00AM Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors (GlobeNewswire) +16.67%
Jan-17-24 08:30AM Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium (GlobeNewswire)
Jan-16-24 08:30AM Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
Jan-11-24 08:30AM Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study (GlobeNewswire)
NCRA - Nocera, Inc. - Stock Price Chart
TickerNCRA [NASD]
CompanyNocera, Inc.
CountryTaiwan
IndustryPackaged Foods
Market Cap15.55MEPS (ttm)-0.41
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.65EPS next 5Y-
P/B4.21EPS Q/Q18.07%
Dividend-Sales Q/Q-24.27%
Insider Own42.81%Inst Own0.97%
Insider Trans0.00%Inst Trans191.69%
Short Float0.07%Earnings-
Analyst Recom1.00Target Price21.77
Avg Volume4.68K52W Range0.97 - 3.10
Apr-16-24 04:00PM Nocera, Inc. Acquires Hangzhou SY Culture Media Co. Ltd., a Douyin Livestreaming e-Commerce Company (ACCESSWIRE) +7.14%
Feb-27-24 09:00AM Nocera, Inc. Explores Strategic Collaboration with Chang Tai Group to Drive Sustainable Innovation in Aquaculture Industry (ACCESSWIRE)
Feb-06-24 04:00PM Nocera, Inc. Completes Strategic Acquisition, Partnering with Zhejiang Xinca Mutual Entertainment Culture Media to Cultivate the Global E-Commerce Market (ACCESSWIRE)
Jan-24-24 10:30AM Nocera Takes Strides in Alabama Fish Farm and Expands its Aquaculture Initiatives in Asian Markets (ACCESSWIRE)
Jan-09-24 03:30PM Nocera Inc. Announces Senior Leadership Change (ACCESSWIRE)
Nov-01-23 03:20PM Nocera Appoints Yiwen Zhang and Song-Yuan Teng to the Board of Directors (ACCESSWIRE)
Jul-18-23 02:00PM Nocera, Inc. Names Cheng Lu Min Huay to its Board of Directors (ACCESSWIRE)
Jul-14-23 01:25AM Nocera, Inc. Announces the Appointment of Grace Lei as Independent Director (ACCESSWIRE)
01:20AM Nocera, Inc. Announces Death of CEO, Jeff Cheng (ACCESSWIRE)
Jun-07-23 02:35PM CORRECTION FROM SOURCE: Nocera, Inc. to Acquire Zhe Jiang Xin Shui Hu Digital Information, Ltd. a Chinese Digital Information Company (ACCESSWIRE)
LGCB - Linkage Global Inc. - Stock Price Chart
TickerLGCB [NASD]
CompanyLinkage Global Inc.
CountryJapan
IndustryInternet Retail
Market Cap71.81MEPS (ttm)-0.03
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S5.64EPS next 5Y-
P/B19.10EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own66.51%Inst Own0.31%
Insider Trans0.00%Inst Trans-
Short Float1.21%Earnings-
Analyst Recom-Target Price-
Avg Volume45.76K52W Range1.28 - 4.30
Apr-22-24 08:30AM Linkage Global Inc's Subsidiary Signs Advertising Deployment Contract with A Major Client for a $40 Million Budgeted Campaign (GlobeNewswire) +11.71%
Apr-17-24 10:32AM Linkage Global Inc Regains Compliance with Nasdaq Filing Requirement (GlobeNewswire)
Mar-28-24 08:00AM Linkage Global Inc Subsidiary to Offer Cross-Border E-commerce Store Operation Services, Unleashing Global Growth Potential (GlobeNewswire) -7.77%
Feb-20-24 07:28PM Linkage Global Inc Receives Notification from Nasdaq Regarding Delayed Form 20-F Filing (GlobeNewswire)
Dec-21-23 04:30PM Linkage Global Inc Announces Closing of $6,000,000 Initial Public Offering (GlobeNewswire) -12.73%
Dec-18-23 06:20PM Linkage Global Inc Announces Pricing of $6,000,000 Initial Public Offering (GlobeNewswire)
QTTB - Q32 Bio Inc. - Stock Price Chart
TickerQTTB [NASD]
CompanyQ32 Bio Inc.
CountryUSA
IndustryBiotechnology
Market Cap296.10MEPS (ttm)-35.16
P/E-EPS this Y57.66%
Forward P/E-EPS next Y9.73%
PEG-EPS past 5Y-0.07%
P/S255.26EPS next 5Y-9.40%
P/B1.10EPS Q/Q53.43%
Dividend-Sales Q/Q-100.00%
Insider Own43.37%Inst Own6.20%
Insider Trans-0.42%Inst Trans-18.59%
Short Float0.15%EarningsNov 14/a
Analyst Recom1.00Target Price47.50
Avg Volume32.71K52W Range8.24 - 30.92
Apr-03-24 07:00AM Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer (PR Newswire)
Mar-18-24 04:30PM Homology Medicines Declares Distribution to Common Stockholders (GlobeNewswire)
Mar-15-24 09:52PM FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023 (InvestorPlace)
Mar-01-24 10:48AM Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Jan-27-24 12:10PM SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX (GlobeNewswire)
Jan-03-24 04:08PM Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Nov-17-23 06:40AM Q32 Bio to merge with Homology Medicines (Pharmaceutical Business Review)
Nov-16-23 12:18PM Homology enters reverse merger with Q32 Bio (BioPharma Dive) -34.99%
07:05AM Q32 Bio and Homology Medicines Announce Merger Agreement (PR Newswire)
Nov-14-23 05:02PM Homology Medicines: Q3 Earnings Snapshot (Associated Press Finance)
CDTG - CDT Environmental Technology Investment Holdings Limited - Stock Price Chart
TickerCDTG [NASD]
CompanyCDT Environmental Technology Investment Holdings Limited
CountryChina
IndustryWaste Management
Market Cap43.23MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q141.30%
Dividend-Sales Q/Q342.90%
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume388.79K52W Range2.76 - 4.60
Apr-22-24 01:57PM CDT Environmental Technology Closes $6 Million IPO (MT Newswires) +7.73%
01:33PM CDT Environmental Technology Investment Holdings Limited Announces Closing of Initial Public Offering (GlobeNewswire)
SBFM - Sunshine Biopharma Inc - Stock Price Chart
TickerSBFM [NASD]
CompanySunshine Biopharma Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap1.43MEPS (ttm)-19.05
P/E-EPS this Y115.79%
Forward P/E0.08EPS next Y466.67%
PEG-EPS past 5Y73.50%
P/S0.06EPS next 5Y-
P/B0.02EPS Q/Q94.97%
Dividend-Sales Q/Q94.94%
Insider Own4.14%Inst Own11.83%
Insider Trans292.78%Inst Trans-
Short Float0.74%EarningsMar 28/b
Analyst Recom1.00Target Price300.00
Avg Volume546.93K52W Range1.73 - 140.00
Apr-19-24 08:00AM Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) (ACCESSWIRE) -46.84%
Apr-12-24 09:00AM Sunshine Biopharma Announces Reverse Stock Split (ACCESSWIRE) -8.04%
Apr-08-24 01:53PM SBFM Stock Earnings: Sunshine Biopharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -5.10%
Apr-01-24 08:00AM Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 (ACCESSWIRE) +76.03%
Mar-04-24 09:18AM Why Is Sunshine Biopharma (SBFM) Stock Down 17% Today? (InvestorPlace) -18.95%
Feb-15-24 09:15AM Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering (ACCESSWIRE) +6.01%
Feb-13-24 09:00AM Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering (ACCESSWIRE) -63.83%
Dec-04-23 08:30AM Sunshine Biopharma Moves Principal Office to New York City (GlobeNewswire) -7.59%
Nov-13-23 08:30AM Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition (ACCESSWIRE) -12.08%
Sep-21-23 09:05PM Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance (ACCESSWIRE) -9.68%
CIFR - Cipher Mining Inc - Stock Price Chart
TickerCIFR [NASD, RUT]
CompanyCipher Mining Inc
CountryUSA
IndustryCapital Markets
Market Cap1.35BEPS (ttm)-0.11
P/E-EPS this Y-2.61%
Forward P/E15.90EPS next Y379.50%
PEG-EPS past 5Y-
P/S10.66EPS next 5Y-
P/B2.70EPS Q/Q118.50%
Dividend-Sales Q/Q1329.67%
Insider Own42.33%Inst Own12.28%
Insider Trans-7.38%Inst Trans-2.18%
Short Float8.22%EarningsMay 07/b
Analyst Recom1.29Target Price5.67
Avg Volume8.96M52W Range1.76 - 5.75
Apr-22-24 09:30AM Wall Street Analysts See Cipher Mining (CIFR) as a Buy: Should You Invest? (Zacks) +18.75%
Apr-18-24 10:53AM What You Need To Know Ahead of The Bitcoin Halving (Investopedia) +7.60%
Apr-17-24 06:15PM Cipher Mining Inc. (CIFR) Rises As Market Takes a Dip: Key Facts (Zacks)
04:05PM Cipher Mining Announces Date of First Quarter 2024 Business Update Conference Call (GlobeNewswire)
Apr-01-24 04:05PM Cipher Mining Announces March 2024 Operational Update (GlobeNewswire) -5.24%
Mar-26-24 02:04PM 11 Crypto Stocks with Biggest Upside (Insider Monkey)
09:40AM Are Business Services Stocks Lagging Cipher Mining (CIFR) This Year? (Zacks)
Mar-25-24 09:55AM Cipher Mining Inc. (CIFR) Now Trades Above Golden Cross: Time to Buy? (Zacks) +13.85%
Mar-07-24 11:33AM Cipher Mining Inc. (NASDAQ:CIFR) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.79%
Mar-05-24 11:53AM CIFR Stock Earnings: Cipher Mining Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
ANL - Adlai Nortye Ltd. ADR - Stock Price Chart
TickerANL [NASD]
CompanyAdlai Nortye Ltd. ADR
CountryChina
IndustryBiotechnology
Market Cap1.35BEPS (ttm)-
P/E-EPS this Y66.80%
Forward P/E-EPS next Y-57.26%
PEG-EPS past 5Y-90.91%
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own0.07%
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom1.00Target Price30.00
Avg Volume7.39K52W Range7.11 - 19.30
Mar-29-24 06:00AM Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development (GlobeNewswire)
Nov-17-23 07:30AM Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC (GlobeNewswire)
Oct-23-23 08:12AM Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award (GlobeNewswire)
Oct-03-23 12:05PM Adlai Nortye Ltd. Announces Closing of Initial Public Offering (GlobeNewswire) -6.87%
Sep-29-23 02:46AM Adlai Nortye Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)
ENTX - Entera Bio Ltd - Stock Price Chart
TickerENTX [NASD]
CompanyEntera Bio Ltd
CountryIsrael
IndustryBiotechnology
Market Cap72.73MEPS (ttm)-0.31
P/E-EPS this Y19.35%
Forward P/E-EPS next Y-116.00%
PEG-EPS past 5Y25.05%
P/S-EPS next 5Y-
P/B7.00EPS Q/Q36.18%
Dividend-Sales Q/Q-100.00%
Insider Own19.90%Inst Own11.45%
Insider Trans0.93%Inst Trans-4.02%
Short Float0.31%EarningsMar 08/a
Analyst Recom1.00Target Price10.00
Avg Volume223.07K52W Range0.52 - 3.35
Apr-18-24 06:15PM Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today (Zacks)
Apr-15-24 03:43PM Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? (InvestorPlace) -15.44%
Apr-12-24 09:40AM Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? (Zacks) +12.03%
Apr-09-24 09:09AM Here's Why You Should Invest in Entera Bio (ENTX) Stock Now (Zacks) +15.38%
Apr-08-24 08:30AM Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research (GlobeNewswire)
Mar-26-24 08:30AM Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months (GlobeNewswire)
Mar-24-24 03:54PM 12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Mar-20-24 08:00AM Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire) +7.79%
Mar-08-24 04:05PM Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-04-24 08:30AM Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +19.44%
1⋯56789101112131415⋯20
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.